1 Hepatitis B-Virus Genotype D is Prevalent in a Multi-Ethnic Population of Karachi, Pakistan

2 Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

3 Poor adherence is a contributor to viral breakthrough in patients with chronic hepatitis B

4 Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients

5 Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B

6 Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs

7 Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

8 Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B

9 Safety and efficacy of entecavir for the treatment of chronic hepatitis B

10 Current treatment of choice for chronic hepatitis C infection

11 New approaches in the management of chronic hepatitis B: role of tenofovir

12 Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

13 Poor adherence is a contributor to viral breakthrough in patients with chronic hepatitis B

14 Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients

15 Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B

16 Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs

17 Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

18 Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B

19 Safety and efficacy of entecavir for the treatment of chronic hepatitis B

20 Current treatment of choice for chronic hepatitis C infection

21 New approaches in the management of chronic hepatitis B: role of tenofovir

22 Effectiveness and Cost-Effectiveness of Triple Therapy with Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis from the Brazilian Public Health System Perspective

23 Clinical factors leading to a change in management in chronic hepatitis B patients managed in a tertiary setting.

24 Real-world effectiveness and safety of Ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan.

25 High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation

26 Tenofovir and telbivudine combination therapy rapidly decreases viral loads in immune-tolerant chronic hepatitis B patients awaiting assisted reproduction: An open-label, randomized, controlled study

27 Electronic health informatics data to describe clearance dynamics of hepatitis B surface antigen (HBsAg) and e antigen (HBeAg) in chronic hepatitis B virus infection

28 Liver fibrosis staging with combination of APRI and FIB-4 scoring systems in chronic hepatitis C as an alternative to transient elastography.

29 A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms

30 Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.

31 Title: p38 mitogen-activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAg-negative chronic hepatitis B.

32 The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: a decision-analytic approach.

33 Quantification of circulating miR-125b-5p predicts survival in chronic hepatitis B patients with acute-on-chronic liver failure.

34 Correlation of CpG methylation of Pdcd1 gene with PD-1 expression on CD8 T cells and medical laboratory indicators in chronic hepatitis B infection.

35 Metabolomics analysis of the saliva in patients with chronic hepatitis B using nuclear magnetic resonance: a pilot study.

36 Changes of liver fibrosis in chronic hepatitis C patients with no response to interferon-alpha therapy: including quantitative assessment by a morphometric method.

37 Surveillance and impact of occult hepatitis B virus, SEN virus, and Torque teno virus in Egyptian hemodialysis patients with chronic hepatitis C virus infection.

38 Evaluation of the /S Gene Overlapping Mutations in Chronic Hepatitis B Patients in Northern Cyprus.

39 The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C.

40 The diagnostic value of a globulin/platelet model for evaluating liver fibrosis in chronic hepatitis B patients

41 Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C.

42 IL28B SNP rs12979860 is the Critical Predictor for Sustained Viral Response in Chinese Children Aged 1 to 6 Years with Chronic Hepatitis C.

43 Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection.

44 Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia.

45 Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C.

46 Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin Regimen for Patients Infected with Chronic Hepatitis C Virus Genotype 1 in Malaysia

47 Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.

48 Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection.

49 Current progress in the development of therapeutic vaccines for chronic hepatitis B virus infection

50 Chronic Hepatitis C Virus Infection in Older Adults

51 Safety and Effectiveness of a Nurse-Led Outreach Program for Assessment and Treatment of Chronic Hepatitis C in the Custodial Setting

52 Family physicians' knowledge and screening of chronic hepatitis and liver cancer

53 Telaprevir for previously untreated chronic hepatitis C virus infection

54 Recent Successes and Noteworthy Future Prospects in the Treatment of Chronic Hepatitis C

55 Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis

56 Liver Biopsy Findings for HIV-Infected Patients with Chronic Hepatitis C and Persistently Normal Levels of Alanine Aminotransferase

57 Simultaneous Acute Hepatitis B Virus and Hepatitis C Virus Infection Leading to Fulminant Hepatitis and Subsequent Chronic Hepatitis C

58 Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States

59 relationship between hbv dna and hbeag in serum and hbcag and inflammation grade in liver tissue among patients with chronic hepatitis b

60 rituximab-containing treatment regimens may imply a long-term risk for difficult-to-treat chronic hepatitis e

61 predictors of the efficiency of short-term interferon-containing therapy using direct-acting antiviral drugs in patients with chronic hepatitis c virus genotype 1

62 portal cd4+ and cd8+ t lymphocyte correlate to intensity of interface hepatitis in chronic hepatitis c a quantificação de cd4+ e cd8+ portal em hepatite c crônica está relacionada com a intensidade da hepatite de interface

63 neuroimaging findings in chronic hepatitis c virus infection: correlation with neurocognitive and neuropsychiatric manifestations

64 viral kinetics during the first month of treatment in patients with genotype 1 chronic hepatitis c cinética viral durante el primer mes de tratamiento en pacientes con hepatitis crónica c genotipo 1

65 characteristic morphological signs of the brain damage during chronic hepatitis c virus infection identified in autopsy samples

66 insulin resistance and chronic hepatitis c

67 comparison of the effectiveness and renal safety of tenofovir versus entecavir in patients with chronic hepatitis b

68 real-time tissue elastography in the evaluation of liver cirrhosis in patients with chronic hepatitis b

69 management of chronic hepatitis c: consensus guidelines

70 intravenous glycyrrhizin improved serum transaminases rapidly in a chronic hepatitis b patient with acute exacerbation

71 comparative efficacy of combined treatment with intron a and pegintron in combination with ribavirin in patients with chronic hepatitis С

72 primary hepatic small-cell carcinoma developed during antiviral treatment for chronic hepatitis b

73 pnpla3 rs1010023 predisposes chronic hepatitis b to hepatic steatosis but improves insulin resistance and glucose metabolism

74 role of t-helper 9 cells in chronic hepatitis c-infected patients

75 research advances in drug resistance to nucleos(t)ide analogues in treatment of chronic hepatitis b

76 interrelation of immunological and clinic-morphological parameters in patients with chronic hepatitis c depending on mixed cryoglobulinemia

77 liver-related morbidity and mortality in patients with chronic hepatitis c and cirrhosis with and without sustained virologic response

78 effects of nucleos(t)ide analogues on estimated glomerular filtration rate and serum creatinine level in patients with chronic hepatitis b

79 lamivudine for the treatment of membranous glomerulopathy secondary to chronic hepatitis b infection

80 effect of entecavir combined with fuzheng huayu capsules on inflammatory factors and fibrosis markers in patients with compensated chronic hepatitis b-related cirrhosis

81 treatment of chronic hepatitis c among injecting drug users: a 5-year follow-up

82 the treatment outcome and impact on blood transfusion demand of peg-interferon/ribavirin in thalassemic patients with chronic hepatitis c

83 case report: safety and efficacy of tocilizumab in a patient with rheumatoid arthritis and chronic hepatitis c

84 hbv genotype distribution and its relationship with serum hbv dna level and hbeag expression among patients with chronic hepatitis b in southern zhejiang province, china

85 comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis b

86 increased oral lichen planus in a chronic hepatitis patient associated with elevated transaminase levels before and after interferon/ribavirin therapy

87 molecular mechanisms of same tcm syndrome for different diseases and different tcm syndrome for same disease in chronic hepatitis b and liver cirrhosis

88 evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis c

89 hepatocyte growth factor in patients with three different stages of chronic liver disease including hepatocellular carcinoma, cirrhosis and chronic hepatitis: an immunohistochemical study

90 direct acting antivirals in patients with chronic hepatitis c and down syndrome

91 efficacy of switching from adefovir to tenofovir in chronic hepatitis b patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (satis study)

92 immunity and fibrogenesis: the role of th17/il-17 axis in hbv and hcv-induced chronic hepatitis and progression to cirrhosis

93 a noninvasive score model for prediction of nash in patients with chronic hepatitis b and nonalcoholic fatty liver disease

94 population changes of colon lumen microbiota in patients with chronic hepatitis c

95 boceprevir-based triple antiviral therapy for chronic hepatitis c virus infection in kidney-transplant candidates

96 spanish multicentre pibhe study: prevalence and immunisation of chronic hepatitis b in haemodialysis patients in spain

97 efficacy of interferon alpha- 2b with or without ribavirin in thalassemia major patients with chronic hepatitis c virus infection: a randomized, double blind, controlled, parallel group trial

98 pharmacokinetic interactions of herbal medicines for the treatment of chronic hepatitis

99 a better antiviral efficacy found in nucleos(t)ide analog (na) combinations with interferon therapy than na monotherapy for hbeag positive chronic hepatitis b: a meta-analysis

100 acute exacerbation in chronic hepatitis b virus infection

101 retreatment with pegylated interferon alpha-2a and ribavirin in patients with chronic hepatitis c who have relapsed or not responded to a first course of pegylated interferon-based therapy

Keyword Connections

Journals

Research Groups

Bibliographies